Biotech News
Context Therapeutics Reports Third Quarter 2025 Operating and Financial Results
ir.contexttherapeutics.com2026-05-06 15:20 EST
Ongoing Phase 1 trial of CTIM-76 (CLDN6 x CD3) demonstrates encouraging antitumor activity and safety Ongoing Phase 1 trial of CT-95 (MSLN x CD3) is approaching target dose levels Cash and cash equivalents of $76.9 million as of September 30, 2025 PHILADELPHIA, Nov.